Verflixt! Es sieht so aus, als wenn Sie einen veralteten Browser benutzen. Wir empfehlen Ihnen dringend Ihren Browser zu aktualisieren.
Weitere Informationen über Browser und Updates finden Sie hier

Dr. Margarete Fischer-Bosch-Institute of Pharmacology

The Dr. Margarete "Fischer-Bosch-Institute" of Clinical Pharmacology (IKP), a research department within the prestigious "Robert-Bosch-Stiftung", has recently made it into the headlines once again. With its breakthrough discoveries in treatment outcomes in breast cancer patients based on genetic polymorphisms, the IKP has positioned itself as one of the leaders in the emerging field of Pharmacogenomics.

Established in 1973 with just 4 researchers, the IKP was established with the goal of improving individualized medicine and drug treatments. Dr. Margarete Fischer-Bosch (1888-1972) was the eldest daughter of Robert Bosch, a German industrialist and founder of the Bosch Trust. She held a PhD in political sciences and donated money for the foundation of the IKP to be affiliated with Robert Bosch Hospital. She had a strong interest to foster the elucidation of drug action and efficacy for the ultimate benefit of patients.

Today, the Institute has grown to over 90 employees whose research still aims to fulfill its original goal by unraveling genotype phenotype relationships for the identification of the molecular basis of drug efficacy to avoid adverse drug effects and to improve drug efficacy. By specializing in the research areas of pharmacogenomics and oncology and collaborating internally with the Robert-Bosch-Krankenhaus and externally with both academic and industry partners, the IKP focuses on trying to answer the question: How does the body respond to both disease and drug treatments? Accordingly, the IKP holds an international reputation in basic and clinical pharmacogenomic research with a dual focus on drug targets including drug metabolizing enzymes, transporters, DNA repair enzymes and variability of drug response such as thiopurine therapy for leukemia and inflammatory bowel disease and anti-hormonal therapy of breast cancer.

The IKP is the leading partner for the FP7 Marie Curie Initial Training Network FightingDrugFailure and will play a vital role in the implementation of this academic training program for young investigators and will coordinate all Early Stage Researcher (ESR) and Experienced Researcher (ER) positions. The IKP has a long standing tradition of training PhD students and young investigators from all over the world, including various countries in Europe as well as China, India, and Japan. In addition to acting as a primary host site, the IKP is responsible for the overall development of the Initial Training Network and will work closely with its partner sites to foster a seamless collaboration.

Early Stage Researchers working at the IKP in Stuttgart will receive a PhD in pharmacogenomics from the University of Tübingen, an affiliate of the IKP and the executer of the ITN program FightingDrugFailure. Located an hour south of Stuttgart, the University of Tübingen hosts ca. 23,000 students annually. Fueled by over 450 Professors and 2000 Scientists and Researchers, the University of Tübingen’s research departments continue to grow and expand, continuously adding new programs to its already rigorous offerings. In the past years, the University of Tübingen has continuously ranked amongst the best universities in Germany.



Dr. Margarete Fischer-Bosch-Institute of Pharmacology

Auerbachstr, 112
70376 Stuttgart
Klinische Forschung
Forschung & Lehre